At Diopsys, Inc., we are dedicated to developing breakthrough eye care technology and encouraging both innovative thinking and a creative, pioneering spirit. The Diopsys Executive Team has significant engineering, management, operations, and sales experience in medical and related fields to help make Diopsys the world leader in modern visual electrophysiology.
Since January 2000, the Diopsys management team has been led by Joseph Fontanetta. Mr. Fontanetta has served as the company’s President and Chief Executive Officer and as a member of the Board of Directors during that period. In addition, he has 30 years’ senior management experience in health care including: Chief Operating Officer at Lawrence Hospital, and Executive Vice President & COO for Franciscan Health Systems. Mr. Fontanetta has also held senior sales and marketing positions at Fortune 500 medical industry companies including: Corning Glass, Bristol-Myers Squibb and Eli Lilly. Mr. Fontanetta received a B.S. in from Fordham University and an M.B.A. from Wagner College.
Executive Vice President, COO
Donald Lepone has served as Executive Vice President, Chief Operating Officer for Diopsys since the Fall of 2003. He has in-depth experience in acquisitions, divestitures, initial public offerings, corporate integrations, marketing, and sales force management. As a consumer products President/CEO, he took a private label health and personal care products start-up from zero to $128 million in sales. Mr. Lepone received a B.S. from the University of Bridgeport, and an M.B.A. from the University of Connecticut.
Vice President, Business Development and Clinical Affairs
Matthew Emmer joined Diopsys in May 2004 as a Sales Manager. He previously held the Vice President – Sales position and is currently Vice President – Business Development and Clinical Affairs. From 2000 through 2004, Mr. Emmer was an Ophthalmology /Surgery Specialist for Lumenis, Inc. Prior to 2000, Mr. Emmer held various senior level position in sales and sales management for companies including Aspect Medical, Spacelabs, Cryomedical Sciences and Advanced Technology Laboratories. Mr. Emmer received his B.A. in Bioengineering from University of California, San Diego.
Alberto González García, M.D.
Chief Medical Officer, Diopsys
Chairman of the Diopsys Scientific Advisory Board
Since 2011, Alberto González García, M.D. has lead Diopsys’ extensive clinical research efforts. Dr. González received his medical training at Finlay-Albarran in Havana, Cuba. He completed fellowships in Neuro-Ophthalmology at the National Institute of Neurology and Neurosurgery in Cuba, and in Glaucoma at the Hamilton Glaucoma Center at the University of California San Diego. He was Chief of the Neuro-Ophthalmology Department at the National Institute of Neurology and Neurosurgery and a clinician and surgeon at the National Institute of Ophthalmology in Cuba. He has published and contributed to numerous books and studies in the areas of early diagnosis of glaucoma, ischemic optic neuropathy, and optic coherence tomography (OCT) in the diagnosis of retina and optic nerve diseases, among many others.
Vice President, Engineering
Laurie Cox joined Diopsys in 2008. Ms. Cox’s prior experience includes engineering positions at Bell Laboratories, black projects for the US Navy and CIA-DoD for algorithm design, data acquisition/analysis, test equipment for Air Force One, F1-11, and President of RLC Designs, providing engineering solutions for more than 20 years. Ms. Cox is a three-time recipient of “Best in Test” Awards for significant contributions to test equipment designs and Excellence in Engineering Awards. She received her B.E. and M.S. in Electrical Engineering from Manhattan College and Rutgers University.
Vice President, Sales (US)
Alan Rich joined Diopsys in January 2004 as a Sales Manager to introduce the Enfant® VEP technology. After a short hiatus, he returned as the Vice President, Sales in January of 2010. Prior to 2010, Mr. Rich held various senior level positions in sales and sales management for companies including Spacelabs, Cryomedical Sciences, Acuson/Siemens Ultrasound, American Edwards Laboratories, and U.S Surgical Corporation. This is the seventh new technology that Mr. Rich has introduced into the medical market place, five of which have changed the standard of care. He received his B.S. in Education from Boston University.
Vice President, International Sales
Bill Shields joined Diopsys in 2016 with over 27 years of sales and international sales management experience in the ophthalmic industry. Mr. Shields comes to Diopsys from Optovue, Inc. where he built and managed an extensive network of distributors covering over 75 countries. Prior to Optovue, Mr. Shields held various management positions with Carl Zeiss Meditec, Laser Diagnostic Technologies, Allergan Medical Optics and Humphrey Instruments. Mr. Shields holds a B.A. in Psychology from Boston University.
Peter Derr, PE
Vice President, Clinical Documentation and Regulatory Affairs
Peter Derr joined Diopsys in 1998 to make electrophysiology accessible to both primary care and eye care practices. He has 37 years of experience in engineering and clinical trials, including work with military radar, IFF (identification friend-or-foe), vision systems development, and industrial process and controls. Prior to Diopsys, Mr. Derr held various management position with ITT, the State of New Jersey, and the United States Navy. He holds a B.S. and M.S. in Electrical Engineering from New Jersey Institute of Technology and is a Board Licensed Engineer in New Jersey and New York.
Vice President, Finance and Human Resources
Scott Kahn has served as Diopsys’ CFO/Controller since July 2006. Prior to joining Diopsys, Mr. Kahn held various management positions with Diamond Chemical Co., Inc., Pharmaceutical Formulations, Inc., and The Eight O’Clock Coffee Company. Mr. Kahn received a B.A. in Accounting from Franklin and Marshall College and an M.B.A. in International Business from Rutgers University. He is a Certified Public Accountant licensed in the state of New York.